Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracellular phosphatidylcholine functions as a noncanonical TLR4 activator to drive adipocyte lipolysis and apoptosis.

Frontiers in pharmacology·2026
Same author

Hepassocin drives EGFR-dependent endothelial atherogenic activation via NOX1/ROS amplification and p38 signaling.

Archives of biochemistry and biophysics·2026
Same author

Modulating cell surface chemistry through mild reduction reinforces extracellular-to-intracellular transmission forces and mechano-signaling.

Materials today. Bio·2026
Same author

Ergosterol Attenuates Palmitate-Induced Tenocyte Apoptosis Through the Suppression of ER Stress and Myocyte-Derived IL-15/METRNL-Mediated Crosstalk.

Mycobiology·2026
Same author

Ginsenoside Rg5 mitigates tenocyte death <i>via</i> SIRT6/autophagy-dependent signaling in an aging model.

Journal of ginseng research·2026
Same author

Population analyses reveal heterogenous encoding in the medial prefrontal cortex during naturalistic foraging.

eLife·2026
Same journal

Neutral Amphiphiles Boost Transfection Efficiency and Reduce Inflammation in Polymer Micelle-Mediated mRNA Delivery.

Bioconjugate chemistry·2026
Same journal

Surfactant-Mediated Buchwald-Hartwig Coupling of Aliphatic Amines for the Synthesis of DNA-Encoded Libraries.

Bioconjugate chemistry·2026
Same journal

Artificial Intelligence for Discovery in Life Sciences.

Bioconjugate chemistry·2026
Same journal

Iron Single Atom Nanozyme-Mediated GPX4 Inhibitor Delivery for Self-Enhanced Ferroptosis.

Bioconjugate chemistry·2026
Same journal

SpyCatcher-Engineered Ferritin Nanocages Enable Dual-Receptor Targeting for Enhanced Glioma Therapy.

Bioconjugate chemistry·2026
Same journal

One-Pot Synthesis of Functionalized Coumarin Fluorophores Enables Rapid Access to Live-Cell Bioorthogonal Labeling and Microenvironmental Sensing Agents.

Bioconjugate chemistry·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

siRNA conjugate delivery systems.

Ji Hoon Jeong1, Hyejung Mok, Yu-Kyoung Oh

  • 1College of Pharmacy, Sungkyunkwan University, Suwon 440-746, South Korea, Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon 305-701, South Korea.

Bioconjugate Chemistry
|December 5, 2008
PubMed
Summary
This summary is machine-generated.

Small interfering RNA (siRNA) bioconjugates enhance drug delivery by linking siRNA to various molecules. This review summarizes recent advancements in siRNA bioconjugate development for improved gene silencing.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Related Experiment Videos

Last Updated: Jun 27, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Area of Science:

  • Bioconjugation Chemistry
  • RNA Therapeutics
  • Nanomedicine

Background:

  • Small interfering RNA (siRNA) holds therapeutic potential but faces delivery challenges.
  • Chemical conjugation of siRNA to various materials aims to improve its properties.
  • Effective delivery is crucial for in vivo gene silencing applications.

Purpose of the Study:

  • To review recent developments in siRNA bioconjugates.
  • To summarize strategies for enhancing siRNA delivery and efficacy.
  • To highlight the characterization and in vitro/in vivo testing of siRNA bioconjugates.

Main Methods:

  • Chemical conjugation of siRNA to diverse molecules (lipids, polymers, peptides, nanomaterials).
  • Synthesis and characterization of novel siRNA bioconjugates.
  • In vitro and in vivo evaluation of gene silencing efficiency.

Main Results:

  • siRNA bioconjugates demonstrate improved pharmacokinetic profiles.
  • Enhanced cellular uptake and target specificity were observed.
  • Successful gene silencing was achieved in various models.

Conclusions:

  • siRNA bioconjugates represent a promising strategy for targeted gene silencing.
  • Further development of siRNA bioconjugates can advance RNA-based therapeutics.
  • Optimized bioconjugation strategies are key to clinical translation.